Admedus Charts An Eclectic Path To A Global Future
Executive Summary
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
You may also be interested in...
German COVID-19 Testing Rate The Envy Of Others, With Demand Set To Climb
Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”
EU Health Innovation Partnership Reflects Medtech’s Role In Unmet Needs
The EU Partnership on Health Innovation, a new public private health care research partnership, is in the final drafting phase before its launch under Horizon Europe. In Vivo asked the partnership’s medtech industry lead, Patrick Boisseau, to set out the innovation challenges for participants as they address unmet health care needs in Europe.
China’s NMPA Steps Up To The Plate In COVID-19 Fight But Much Is Left To Do
Chinese monitoring of the spread of COVID-19 locally has reported no new cases of home-grown infection in a single day for the first time since the outbreak began. It indicates control efforts, including the NMPA’s fast-tracking of relevant devices, PPE and IVDs, are having the desired effects.
Need a specific report? 1000+ reports available
Buy Reports